OREANDA-NEWS. Takeda Pharmaceutical Company Limited today announced revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize multiple molecules / products from Amgen’s pipeline for the Japanese market.  By the revisions, such rights for molecules / products including AMG403 and AMG386 will be returned to Amgen, effective immediately.

Takeda and Amgen will continue to collaborate on the development and commercialization of remaining molecules / products for the Japanese market, including Vectibix® (panitumumab), a leading treatment for unresectable advanced or recurrent colorectal cancer.

“Through our work with Amgen, we have successfully delivered Vectibix to the Japanese patients facing a challenging diagnosis while continuing to build our scientific understanding of novel treatment pathways,” said Phil Rowlands, Interim Head, Oncology Therapeutic Area Unit, Takeda.  “We look forward to continuing our scientific discovery and to building a portfolio of innovative medicines through our ongoing collaboration with Amgen.”

Takeda will work with Amgen to ensure a smooth transition of these molecules / products, and will cooperate with Amgen to ensure patients who receives study drug that include any of such molecules / products will receive appropriate therapies in Japan.

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation.  More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.